Regulatory Affairs Professionals Society: FDA Advisory Committee Backs Two More Peptides, Rejects One for Compounding List Post-meeting reporting documenting the six favorable recommendations and the unfavorable emideltide/DSIP vote
Because retatrutide does not hold a marketing authorisation in the UK, it is unlawful to sell, supply, or advertise it as a medicinal product under the Human Medicines Regulations 2012 (HMR 2012)
The FDA has not yet removed the semaglutide drugs from its shortage list
(2023, The Lancet) Type 2 Diabetes Trial Study Design: Randomized, double-blind, placebo- and active-controlled Phase 2 trial in adults with type 2 diabetes
Chronic stress can disrupt the menstrual cycle, leading to irregular or missed periods
The only lawful way to receive it is enrollment in a clinical trial